RNA therapy company Ionis Pharmaceuticals Inc (Nasdaq: IONS) on Monday announced positive topline results from the Phase 3 Essence study of olezarsen in patients with moderate hypertriglyceridemia and at risk for atherosclerotic cardiovascular disease.
Olezarsen achieved the study's primary endpoint, delivering statistically significant reductions in triglyceride levels of 61% and 58% versus placebo at monthly doses of 80 mg and 50 mg, respectively (p
Sarepta receives UK approval to continue dosing in ELEVIDYS ENVISION study
Ionis reports positive Phase 3 results for olezarsen in moderate hypertriglyceridemia
Nordic Bioscience launches new Endotrophin assay
AbbVie and ADARx Pharmaceuticals partner on next-generation siRNA therapies
Otsuka's leukaemia drug ponatinib launched on Fangzhou platform
FDA accepts Novo Nordisk's filing application for oral semaglutide 25 mg
Avacta Therapeutics reports positive Phase 1 data for lead candidate
Innovent's limertinib receives Chinese regulatory approval for first-line treatment of lung cancer
Primo Biotechnology's Taoyuan facility granted PIC/S GMP Certification
Renibus Therapeutics completes RBT-1 Phase 3 clinical trial enrolment
Rona Therapeutics granted Chinese approval of IND application for hypertension drug candidate RN1871
Clario partners with AWS on advancing clinical data analysis with generative AI
Langhua Pharmaceutical passes US FDA's on-site inspection
Abbott receives CE Mark for Volt Pulsed Field Ablation System to treat atrial fibrillation